Click here for the CME evaluation / post-test
Activity Index
Click on the titles below to view the presentations.
Session I: Plenary session: Advances in IBD
Co-Moderators: Gary R. Lichtenstein, MD, and R. Balfour Sartor, MD
What the clinician should know about genetics in IBD
Judy H. Cho, MD
What the clinician should know about the immune system in IBD
Richard P. MacDermott, MD
Current biologic therapies in IBD
Stephen B. Hanauer, MD
Future therapies in IBD
William J. Sandborn, MD
Session II: Selected clinical topics in IBD
Co-Moderators: Maria T. Abreu, MD, and Russell D. Cohen, MD
Drug safety issues in IBD
Gary R. Lichtenstein, MD
Surrogate endpoints and altering the natural history of IBD
Peter Higgins, MD, PhD
Cancer surveillance and chemoprevention in IBD
David T. Rubin, MD
Fertility and pregnancy in IBD
Uma Mahadevan, MD
Session III: Case-based break-out sessions
Controversies and new techniques for cancer surveillance in Crohn’s Disease and ulcerative colitis: What should we do about low grade dysplasia, polyps and therapy to prevent cancer development?
Francis A. Farraye, MD and Thomas A. Ullman, MD
Session IV: Clinical research in IBD
Co-Moderators: Peter Higgins, MD, PhD and Edward V. Loftus, Jr., MD
Presentations
(This section is not certified for AMA PRA Category 1 CreditTM)
Risk of cervical cancer in IBD patients by IBD medication use
Susan Hutfless
Previous history of steroid use does not preclude treatment with mesalamine in ulcerative colitis
Gary Lichtenstein, MD
Immune determinants of linear growth failure in pediatric Crohn’s disease
Lee Denson
Placebo response in the therapy of Crohn’s disease: A comprehensive analysis of primary data from 733 patients from 13 randomized, Controlled trials
Susanna Nikolaus
Expert Algorithms based on common lab tests outperform Thiopurine Metabolites in the prediction of Thiopurine treatment success in inflammatory bowel disease
Albar Waljee
Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: Colectomy analysis from ACT 1 and ACT 2
William J. Sandborn, MD
An evaluation of Adalimumab on the risk of hospitalization in patients with Crohn’s disease, Data from CHARM
Brian G. Feagan
A multicenter, randomized, phase 2A study of human monoclonal antibody to IL-12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn's disease
William J. Sandborn, MD
Session V: Advances in management of IBD
Co-Moderators: Uma Mahadevan, MD and Bruce E. Sands, MD
Advances in surgery in IBD
Victor W. Fazio, MD
Perianal disease and fistulae in Crohn’s disease
David A. Schwartz, MD
The dysfunctional pouch
Bo Shen, MD
Ostomy care: approach to common stoma problems
Jan Colwell, RN, MS, CWOCN
Session VI: Debates: Current controversies in IBD
Co-Moderators: Marla C. Dubinsky, MD and William J. Tremaine, MD
Debate: When starting biologics, should one continue using immunomodulators?
Pro: Stephen B. Hanauer, MD
Con:
Daniel H. Present, MD
Debate: Is mucosal healing an important clinical end-point in all patients with ulcerative colitis?
Pro: Sunandra V. Kane, MD
Con: Asher A. Kornbluth, MD
Session VII: Case based breakout sessions
Co-Moderators: Marla C. Dubinsky, MD and William J. Tremaine, MD
Immunomodulators and biologics in pediatric IBD: When and how long to use
Robert N. Baldassano, MD and Joel R. Rosh, MD
Session VIII: Selected clinical topics in IBD
Co-Moderators: Asher A. Kornbluth, MD and Corey A. Siegel, MD
Ethical issues concerning IBD clinical trials
William J. Tremaine, MD
Treating the adolescent with IBD
Athos Bousvaros, MD
Lymphomas in IBD patients: Role of disease and medications, prevention and therapy
Edward V. Loftus, Jr., MD
How to Help the IBD Patient Deal Effectively with Chronic Pain
Russell D. Cohen, MD
Session IX: State of the art lectures: Advances in translational research in IBD
Moderator: Jonathan Braun, MD, PhD
Future clinical implications of IBD genetics
Maria T. Abreu, MD
Future strategies targeting the innate immune system for IBD treatment
Lloyd F. Mayer, MD
Future strategies targeting the adaptive immune system for IBD treatment
Scott E. Plevy, MD
Systems biology approach to IBD: Integration of genetic, immunologic and microbiologic data for better future clinical decision making
Stefan Schreiber, MD
Session X: Original clinical and translational research abstract presentations
Co-Moderators: Ivan J. Fuss, MD and Scott E. Plevy, MD
Oral abstract presentations
(This section is not certified for AMA PRA Category 1 CreditTM)
O-031 Primary Sclerosing Cholangitis increases Backwash Ileitis in patients with Ileal Pouch-anal Anastomosis
Katherine Freeman
Sustainability of Adalimumab in fistula healing and response: 2-Year data from CHARM and an open-label extension follow-up study
Jean- Frédéric Colombel
O-028 Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECiSE 2 and its extension studies (PRECiSE 3 and 4)
Stefan Schreiber
O-029 The development of fistulizing and fibrosing complications of Crohn's disease in a pediatric cohort
Neera Gupta
O-030 Capsule endoscopy (CE) in suspected Crohn's disease (CD) in children
Manoj Shah
O-033 Natalizumab induces and maintains continuous response and remission in patients with active Crohn’s disease despite prior anti-tumor Necrosis Factor-Alpha treatment
Stephen B. Hanauer
Click here for the CME evaluation / post-test
|
